- Conditions
- Post Bariatric Hypoglycemia
- Interventions
- Avexitide, Placebo
- Drug · Other
- Lead sponsor
- Amylyx Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 21
- States / cities
- Stanford, California • Aurora, Colorado • Jacksonville, Florida + 16 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 337–360
of 446
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Type 2 Diabetes, Comparative Effectiveness of Glycemia-lowering Medications
- Interventions
- Sulfonylurea (glimepiride), DPP-4 inhibitor (sitagliptin), GLP-1 receptor agonist (liraglutide), Insulin (glargine)
- Drug
- Lead sponsor
- GRADE Study Group
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 7,850 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2021
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 28 more
- Conditions
- Gestational Diabetes Mellitus, Type 2 Diabetes Mellitus, Metabolic Syndrome, Impaired Glucose Tolerance, Disorder of Glucose Regulation
- Interventions
- Metformin XR plus placebo, Metformin XR plus liraglutide
- Drug
- Lead sponsor
- Woman's
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 153 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2019
- U.S. locations
- 1
- States / cities
- Baton Rouge, Louisiana
- Conditions
- Diabetes
- Interventions
- Liraglutide, DPP-4 inhibitor
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 50 Years to 120 Years
- Enrollment
- 168,690 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Muscle Loss, Obesity
- Interventions
- Enobosarm, Semaglutide
- Drug
- Lead sponsor
- Veru Inc.
- Industry
- Eligibility
- 60 Years to 100 Years
- Enrollment
- 168 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 14
- States / cities
- Anniston, Alabama • Cullman, Alabama • San Diego, California + 11 more
- Conditions
- Obesity, Breast Cancer Risk
- Interventions
- tirzepatide
- Drug
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 40 Years to 64 Years · Female only
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 2
- States / cities
- Kansas City, Kansas • Westwood, Kansas
- Conditions
- NAFLD, Diabetes, Obesity
- Interventions
- GLP-1 receptor agonist
- Drug
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Obesity, Overweight
- Interventions
- Bimagrumab, Tirzepatide, Bimagrumab Placebo, Tirzepatide Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 25
- States / cities
- Yuma, Arizona • Lake Forest, California • Long Beach, California + 22 more
- Conditions
- Obesity
- Interventions
- Semaglutide, Orlistat, Phentermine/Topiramate, Naltrexone/Bupropion, Liraglutide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Loma Linda, California
- Conditions
- Metabolic Syndrome
- Interventions
- Liraglutide, Exercise training, Liraglutide + Exercise training
- Drug · Other
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 21 Years to 60 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Albiglutide, Auto-injector
- Drug · Device
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- Not listed
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 27
- States / cities
- Phoenix, Arizona • Fresno, California • Lomita, California + 22 more
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- liraglutide, alpha-glucosidase inhibitors, DPP-4 inhibitors, meglitinides, SGLT-2 inhibitors, sulphonylurea, thiazolidinediones
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,991 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 179
- States / cities
- Birmingham, Alabama • Haleyville, Alabama • Tuscumbia, Alabama + 157 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Tirzepatide, Insulin Degludec
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,444 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 33
- States / cities
- Little Rock, Arkansas • Fresno, California • Huntington Park, California + 28 more
- Conditions
- Obesity, Overweight
- Interventions
- LY3305677, LY3841136, Tirzepatide, LY3549492, LY3532226, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,481 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 49
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 44 more
- Conditions
- CABG
- Interventions
- Placebo, GLP-1 (7-36) amide
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Metabolism and Nutrition Disorder, Obesity
- Interventions
- NNC9204-0530, liraglutide, placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 187 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 2
- States / cities
- Tempe, Arizona • Lincoln, Nebraska
- Conditions
- Obesity, Weight Gain
- Interventions
- Tirzepatide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Sacramento, California • Wilmington, Delaware + 11 more
- Conditions
- Obesity, Overweight
- Interventions
- LY3841136, Tirzepatide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 367 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 48
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 42 more
- Conditions
- Diabetes Mellitus, Type 1, Overweight, Obesity
- Interventions
- Tirzepatide, Acetaminophen, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Diabetic Nephropathies, Kidney Diseases, Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2
- Interventions
- Sodium-glucose cotransporter 2 inhibitors (SGLT2i), Renin-angiotensin-aldosterone system blockade, Glucagon-like peptide-1 receptor agonists (GLP 1 RA), Mineralocorticoid Receptor Antagonists(MRAs)
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Type 1 Diabetes
- Interventions
- ePID closed loop system, liraglutide
- Device · Drug
- Lead sponsor
- Jennifer Sherr
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Obesity, Obese, Overweight or Obesity
- Interventions
- Bimagrumab, Semaglutide, Placebo
- Biological · Drug · Other
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 507 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 10
- States / cities
- Anniston, Alabama • Cullman, Alabama • Hialeah, Florida + 7 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Semaglutide
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 65 Years and older · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Obesity and Overweight, HIV, Chronic Inflammation
- Interventions
- Tirzepatide
- Drug
- Lead sponsor
- University of Hawaii
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Honolulu, Hawaii